Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOVER-AUTONOMIC: Ivabradine for Long COVID Symptoms
NCT06305806Phase 2Completed
- Sponsor
- Kanecia Obie Zimmerman
- Start
- Mar 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ivabradine in post-COVID-19 condition (PCC), autonomic dysfunction and postural orthostatic tachycardia syndrome (POTS) (4 arms), sponsored by Kanecia Obie Zimmerman. Primary endpoint: Orthostatic Hypotension Questionnaire/Orthostatic Intolerance Questionnaire Composite Score at 3 months. Started Mar 2024; status: completed.
02
Drugs
ivabradine
03
Conditions
post-COVID-19 condition (PCC)autonomic dysfunctionpostural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on NCT06305806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06305806.